Aldeyra Therapeutics

Devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

[Aldeyra Therapeutics @AldeyraALDX]

Aldeyra is pleased to announce that the FDA has accepted for Priority Review the Company’s New Drug Application for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma.
Learn more: https://t.co/L5KkNzUrSo

[Aldeyra Therapeutics @AldeyraALDX]

Today, we recognize the 6,000+ rare diseases that affect more than 300 million people worldwide. We have made it our mission to develop innovative therapies that have the potential to improve the lives of patients who suffer from certain large and rare diseases. #RareDiseaseDay

[Aldeyra Therapeutics @AldeyraALDX]

Tune in for #ALDX President and CEO Dr. Todd Brady’s fireside chat with SVB Securities Senior Research Analyst Marc Goodman. We are looking forward to discussing our pipeline and planned clinical milestones today beginning at 10:00 AM ET: https://t.co/1QAqf5MJp0

[Aldeyra Therapeutics @AldeyraALDX]

Today, Aldeyra announced that the FDA has accepted the New Drug Application for topical ocular reproxalap, an investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. Click here to learn more: https://t.co/TdhGLuWN7e

[Aldeyra Therapeutics @AldeyraALDX]

Significant clinical unmet need remains in treating dry eye disease today as the standard of care often requires weeks or months to demonstrate activity. #dryeye #eyecare #optometry #ophthalmology

[Aldeyra Therapeutics @AldeyraALDX]

For the approximately 39 million patients in the United States with dry eye disease, the ocular pain, dryness, and gritty sensation are all too familiar and persistent symptoms of the disease. #dryeye #eyecare #optometry #ophthalmology

[Aldeyra Therapeutics @AldeyraALDX]

July is #DryEyeAwareness month: At Aldeyra, we recognize eye health’s essential role in overall health and have made it our #mission to develop safe and effective treatments that improve the lives of patients with significant unmet medical needs. #dryeye #optometry #ophthalmology

[Aldeyra Therapeutics @AldeyraALDX]

Thanks to #MODLive2022 for the opportunity to present at the 2022 meeting! During the Therapeutics Pipeline session “The Future of Optometry – Pipeline Game Changers” Kelly Mizer, our VP, Commercial Strategy & Operations, provided a dry eye disease program update on reproxalap.

[Aldeyra Therapeutics @AldeyraALDX]

Thanks @ASCRSFoundation for hosting this year’s #ASCRS2022 annual meeting! We appreciated the opportunity to exhibit and share information about Aldeyra and our investigational programs.

[Aldeyra Therapeutics @AldeyraALDX]

Thanks @ASCRSFoundation for hosting this year’s #ASCRS2022 annual meeting! Thanks Dr. Edward J. Holland for your presentation on the results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial. Click here to read the abstract: https://t.co/KIn1FMbwto

[Aldeyra Therapeutics @AldeyraALDX]

Dr. Edward J. Holland is presenting at #ASCRS2022! The presentation on the results of the Phase 3 TRANQUILITY Study Run-In Cohort in Dry Eye Disease will occur today during the Ocular Surface Disease III paper session. Learn more: https://t.co/KIn1FMbwto

[Aldeyra Therapeutics @AldeyraALDX]

Dr. Edward J. Holland will be presenting at the #ASCRS2022 annual meeting! The presentation on the results of the Phase 3 TRANQUILITY Study Run-In Cohort in Dry Eye Disease will occur on April 23 during the Ocular Surface Disease III paper session.

[Aldeyra Therapeutics @AldeyraALDX]

We are looking forward to seeing you at #ASCRS2022! Visit our booth #2657 from April 23 to April 25, to learn about Aldeyra and our investigational programs.

[Aldeyra Therapeutics @AldeyraALDX]

Meet us in Washington D.C. at #ASCRS2022 from April 22 to April 26. We are thrilled to be exhibiting. Stop by our #ASCRS2022 booth #2657 to learn about Aldeyra and our investigational programs.

[Aldeyra Therapeutics @AldeyraALDX]

Thanks to the investors and analysts who attended our R&D Day in New York City, and our featured speakers, Geoffrey M. Thiele and Michael J. Duryee. To hear a replay of our R&D Day webcast and view the slide presentation, click here: https://t.co/ouoHFsEbXe

[Aldeyra Therapeutics @AldeyraALDX]

Excited to be in NYC for our R&D Day! We’re announcing top-line data from Phase 2 proof-of-concept clinical trials of ADX-629, our systemic RASP modulator platform, and the new indications for clinical development. Listen to the webcast starting at 10 am: https://t.co/vdbwh7exaR

[Aldeyra Therapeutics @AldeyraALDX]

We are excited to announce #positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of #reproxalap versus #Xiidra® in patients with dry eye disease.
Find out more: https://t.co/ooiJxsqSJR

[Aldeyra Therapeutics @AldeyraALDX]

Thrilled to have had the opportunity to discuss our investigational #retinalprogram and pipeline at the @Eyecelerator@AAO 2021 Conference! Curious? Check out #ALDX President and CEO Dr. Todd Brady’s Eyewire interview: https://t.co/5wLo8DShCv
#eyecare #retinaldisease #eyecelerator

[Aldeyra Therapeutics @AldeyraALDX]

Today, Aldeyra celebrates #World #Sight #Day! It is our #mission to develop safe and effective treatments that improve the lives of patients with significant unmet medical needs. #LoveYourEyes by pledging to have a sight test or care for your eyes: https://t.co/VJh7j2e0lN

[Aldeyra Therapeutics @AldeyraALDX]

Clinical Ophthalmology published the results of a study comparing the comfort of our lead RASP inhibitor, reproxalap, with lifitegrast in dry eye disease patients. Reproxalap consistently scored higher than lifitegrast on the measures of eye drop comfort: https://t.co/pkpbo03V3b